Point72 Asset Management
ANIK icon

Point72 Asset Management’s Anika Therapeutics ANIK Stock Holding History

Point72 Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Sell
22,515
-6,714
-23% -$99.5K ﹤0.01% 3347
2026
Q1 		$424K Sell
29,229
-28,874
-50% -$335K ﹤0.01% 3195
2025
Q4 		$558K Buy
+58,103
New +$556K ﹤0.01% 3182
2023
Q4 		– Sell
-13,947
Closed -$260K – 2137
2023
Q3 		$260K Buy
+13,947
New +$289K ﹤0.01% 1699

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Point72 Asset Management's ANIK Position: Q2 2026 in Review

Point72 Asset Management reduced its Anika Therapeutics (ANIK) stake by 23% in Q2 2026, selling an estimated $99.5K and leaving 22,515 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #3347.

Point72 Asset Management first reported a position in ANIK in Q3 2023 and has held it in 4 quarters since. The position peaked at $558K in Q4 2025. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Point72 Asset Management held 22,515 shares of Anika Therapeutics worth $329K as of Q2 2026.
  • Point72 Asset Management sold 6,714 Anika Therapeutics shares in Q2 2026, an estimated $99.5K.
  • Anika Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3347 holding.
  • Point72 Asset Management first reported a position in Anika Therapeutics in Q3 2023 and has held it in 4 quarters since.
  • Point72 Asset Management's Anika Therapeutics position peaked at $558K in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.